NEW YORK, NY–(Marketwired – December 17, 2014) – In the news release, “Key Growth Opportunities: KSA Interviews Delmar Pharmaceutical, Critical Control Solutions Corp and Cemtrex, Inc.,” issued earlier today by Marketwired, please be advised that the headline was reported erroneously. The corrected title should read: Key Growth Opportunities: WSA Interviews Delmar Pharmaceutical, Critical Control Solutions Corp and Cemtrex, Inc. Complete corrected text follows.
Key Growth Opportunities: WSA Interviews Delmar Pharmaceutical, Critical Control Solutions Corp and Cemtrex, Inc.
Wall Street Analyzer’s CEO Interview Series
NEW YORK, NY — December 17, 2014 — Delmar Pharmaceutical’s (OTCQX: DMPI) CEO Jeff Bacha took time to update listeners on the company’s lead compound, VAL-083 and it’s clinical applications. He talked about how VAL-083 is able to penetrate the elusive blood brain barrier and therefore has potential in treating Glioblastoma in patients that have failed first and second-line therapy. He added that this molecule is also approved in China for the treatment of lung cancer so Delmar has also been generating new preclinical data to reposition the product. Mr. Bacha elaborated on the company’s key goals for the next 12 months, the main one being to complete dose escalation and advance into a registration directed trial, which will position them to file for an approval with the FDA regarding refractory Glioblastoma.
Critical Control Solutions Corp’s (TSX: CCZ) CEO Alykhan Mamdani discussed the launch of their ProTrend software into the Oil and Gas markets in the US. He stated ProTrend meets a growing demand for the management of key production data and access to information as more producers are drilling outside their parameters. Mr. Mamdani feels the product is unique because it is entirely cloud based and there are no upfront licensing fees and the client is able to pay as they go. He discussed the company’s goal of continuing to expand geographically in the US by opening up more offices. In addition Mr. Mamdani feels CCZ is a good investment opportunity because of a strong balance sheet, significant institutional backing, and recurring revenue opportunities.
Cemtrex, Inc. (OTCBB: CTEI) CEO Saagar Govil highlighted the drivers behind the company’s fiscal Q4 results which saw a revenue increase of over 250%. He attributed this rise to their acquisition of an electronics manufacturing business and strong organic growth as demand for their environmental products grew. Cemtrex is capitalizing on key trends in their manufacturing business by targeting the medical device space, which has grown as a result of the Affordable Healthcare Act. Mr. Govil, who recently received a Top 40 under 40 award from Stony Brook University, also highlighted the company’s acquisition strategy and stated that the market is favorable for these opportunities because of low interest rates. He feels that what sets Cemtrex apart from the competition is their customer service and ability to deliver a quality product in a timely manner.
The Wall Street Analyzer’s aim is to provide investors with the tools they need to make informed decisions on holding stocks. Our staff includes a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before the rest of the market uncovers them, and on the other hand our media experience allows us to produce interviews, which appeal to a larger audience. We provide a format in which more individual investors can understand a featured companies’ upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easier to understand data. Visit: http://www.wallstreetanalyzer.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as SLWF or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, such statements in this release that describe the company’s business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, and risk inherent in the operations of a company. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events or other factors.